Stephen Willey

just wondering if you can provide some more detail around the mechanics of dose escalation just in terms of the platelet response criteria

just elaborate on why you think that's the right target exposure if that's somehow limited by cross-reactivity on wild type

I was just wondering if you could give a little bit of color around what we should expect to see within the abstract publication next week

Can you say anything about the characteristics of the MF patients enrolled into the Phase I with respect to just baseline cytopenias, hemoglobin

the percentage of patients that you're expecting to be titrated up to the highest 1280 dose.

Just curious if you're expecting the majority of patient reauthorizations to occur 6 months after starting therapy

should we assume that the single Phase III PAH trial that you reached alignment on with FDA will be looking at a patient population that's similar to the Phase II?

Should we expect registration of TPIP development in PAH to be limited to a single Phase III trial?

do you have any update on the percentage of PAH patients from the Phase 2 study that have chosen to participate in the open-label extension